acarix Corporate Information, English, IR, MAR, News, Other Corporate Information, Regulatory November 18, 2024 22 Nov 2022 Acarix resolves on a partially guaranteed rights issue of approximately SEK 52.9 million THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, A... Continue reading
acarix Corporate Information, English, IR, News, Other Corporate Information November 18, 2024 18 Nov 2022 Acarix presents at Redeye Life Science Day 2022 On November 24th at 14.50 CET Helen Ljungdahl Round, CEO of Acarix, will discuss the latest developments in the company in an in-depth ... Continue reading
acarix Corporate Information, IR, News, Other Corporate Information, Swedish November 18, 2024 18 Nov 2022 Acarix presenterar på Redeye Life Science Day 2022 Den 24 november kl 14.50 kommer Helen Ljungdahl Round, VD för Acarix, att diskutera den senaste utvecklingen inom företaget i... Continue reading
acarix English, Interim, IR, MAR, News, Q3, Regulatory, Report November 18, 2024 16 Nov 2022 Full focus on the US market with strong interest from healthcare providers, reimbursement code in place and collaboration with ACC Acarix is now taking an important strategic step, putting full commercial focus on the US market. We have the key building blocks in pl... Continue reading
acarix Interim, IR, MAR, News, Q3, Regulatory, Report, Swedish November 18, 2024 16 Nov 2022 Fullt fokus på USA med stort intresse från sjukvården, egen reimbursementkod på plats och samarbete med ACC Acarix tar nu ett viktigt strategiskt kliv och lägger fullt kommersiellt fokus på USA-marknaden. Vi har de viktiga byggstena... Continue reading
acarix Corporate Information, English, IR, News, Other Corporate Information November 18, 2024 15 Nov 2022 Invitation to presentation of Acarix´s third quarter report 2022 Acarix will publish its third quarter results on Wednesday 16 November 2022 at 08.00 am (CEST). A live webcast will be held at 16.30 (C... Continue reading
acarix Corporate Information, IR, News, Other Corporate Information, Swedish November 18, 2024 15 Nov 2022 Inbjudan till presentation av Acarix delårsrapport för tredje kvartalet 2022 Acarix publicerar sin rapport för tredje kvartalet onsdagen den 16 november 2022 kl 08.00. En direktsänd websändning kom... Continue reading
acarix Corporate Information, English, IR, News, Other Corporate Information November 18, 2024 28 Sep 2022 Patient enrollment completed in the FILTER-SCAD randomized controlled multi-center trial The FILTER-SCAD study is a randomized controlled clinical trial including more than 2,000 patients with suspected coronary artery disea... Continue reading
acarix Corporate Information, IR, News, Other Corporate Information, Swedish November 18, 2024 28 Sep 2022 Patientrekrytering slutförd för den randomiserade kontrollerade multicenterstudien FILTER-SCAD FILTER-SCAD-studien är en randomiserad kontrollerad klinisk prövning med fler än 2 000 patienter med misstänkta kra... Continue reading
acarix Corporate Information, English, IR, MAR, News, Other Corporate Information, Regulatory November 18, 2024 26 Sep 2022 Acarix and the American College of Cardiology announce strategic collaboration The American College of Cardiology (“ACC”) and Acarix have signed a strategic collaboration agreement with the goal to deve... Continue reading
acarix Corporate Information, IR, MAR, News, Other Corporate Information, Regulatory, Swedish November 18, 2024 26 Sep 2022 Acarix och American College of Cardiology tecknar strategiskt samarbete American College of Cardiology (“ACC”) och Acarix har tecknat ett strategiskt samarbetsavtal med syfte att utveckla ett kli... Continue reading
acarix Corporate Information, English, IR, News, Other Corporate Information November 18, 2024 22 Sep 2022 Acarix presents at the Redeye event, Theme: Diagnostics On September 27 at 11.30 am CEST, Helen Ljungdahl Round, President and CEO at Acarix will present the company´s latest developmen... Continue reading